Clinical trials: Clinical Research
Acute Agitation
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a…
- Trial name
- SNAP101 (NCT03624322)
- Testing
- Zyprexa IM, Zydis, INP105
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Vitiligo
A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo
This is a study that is being conducted in order to assess the efficacy of microneedling as a stand-alone treatment for vitiligo.
- Trial name
- NCT05053022
- Testing
- Skinpen Precision System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Crown Laboratories, Inc.
Healthy
Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers
The primary objective of this study is to characterise the effects of tipranavir 500 mg and ritonavir 200 mg (TPV/r; given twice daily) at steady-state on the pharmacokinetics of methadone administered as a single dose in healthy…
- Trial name
- NCT02245451
- Testing
- Tipranavir, Ritonavir, Methadone
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Bipolar I Disorder, Schizophrenia
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
- Trial name
- NCT04987229
- Testing
- OLZ/SAM
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 236 people
- Sponsor
- Alkermes, Inc.
Venous Vascular Closure, Electrophysiology Study
Mobilization and Outcomes After Venous Closure
The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in…
- Trial name
- MOVE (NCT07246902)
- Testing
- MYNX CONTROLTM VENOUS Vascular Closure Device
- Where
- 9 sites in United States
- Volunteers
- 339 people
- Sponsor
- Cordis US Corp.
Acute Ischemic Stroke, Intracranial Aneurysms
Intracranial Distal Access Catheter in Neurointerventional Therapy
The study objective is to evaluate the safety and effectiveness of Intracranial Distal Access Catheter in neurointerventional therapy.
- Trial name
- NCT06989931
- Testing
- Intracranial Distal Access Catheter
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- MicroPort NeuroTech Co., Ltd.
Diabetes Mellitus, Type 2
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment…
- Trial name
- NCT00500331
- Testing
- GSK189075, pioglitazone
- Where
- 136 sites in United States, Argentina and 17 more
- Volunteers
- 334 people
- Sponsor
- GlaxoSmithKline
Infective Disorder
Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects
This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects
- Trial name
- NCT07239453
- Testing
- DA-2902, DA-2902-R
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Macular Degeneration
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
- Trial name
- NCT00259753
- Testing
- Bevasiranib
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- OPKO Health, Inc.
Healthy
A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule
The main objective of this trial is to investigate the relative bioavailability of 100 mg nintedanib given as four capsules of 25 mg nintedanib compared with one capsule of 100 mg nintedanib.
- Trial name
- NCT04938453
- Testing
- nintedanib 25 mg, nintedanib 100 mg
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Failure, Heart Decompensation
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE EARLY (NCT01064037)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 70 sites in United States, Canada and 14 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Thrombosis
Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants
Assess the pharmacokinetics (fasting and fed), safety, and tolerability of BMS-986177 following oral dosing of Form A and Form B
- Trial name
- NCT03362437
- Testing
- BMS-986177
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Irritable Bowel Syndrome
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
- Trial name
- NCT01545037
- Testing
- L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
- Where
- 3 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.
Chronic Kidney Disease, Stage 5
Head to Head Study Against Sevelamer Hydrochloride
To compare the efficacy of Fosrenol (Lanthanum carbonate) and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline.
- Trial name
- NCT00441545
- Testing
- Fosrenol (Lanthanum Carbonate), Sevelamer hydrochloride
- Where
- 44 sites in United States, Germany and 2 more
- Volunteers
- 182 people
- Sponsor
- Shire
Healthy Volunteers
Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers
Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple ascending doses of MORF-057 in healthy subjects.
- Trial name
- NCT04580745
- Testing
- MORF-057
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Hepatitis C, Chronic
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)
SCH 900518 is a potent oral inhibitor of HCV NS3 protease which disrupts hepatitis C virus (HCV) polyprotein processing. SCH 900518, when added to the current standard of care (SOC), peginterferon-alfa plus ribavirin, would…
- Trial name
- NEXT-1 (NCT00797745)
- Testing
- peginterferon alfa 2b, ribavirin, SCH 900518
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Study of COVID-19 DNA Vaccine (AG0301-COVID19)
This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.
- Trial name
- NCT04463472
- Testing
- AG0301-COVID19
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Cytomegalovirus Infections, HIV Infections
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts <=…
- Trial name
- NCT00002095
- Testing
- Ganciclovir
- Where
- 19 sites in United States
- Volunteers
- 700 people
- Sponsor
- Hoffmann-La Roche
Advanced Melanoma
Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma
The purpose of this arm of the study is to find the best way to give patients this investigational product and determine if it can treat advanced melanoma by stimulating the immune system.
- Trial name
- NCT03989895
- Testing
- Dengue Virus-1 #45AZ5 (PV-001-DV)
- Volunteers
- 10 people
- Sponsor
- PrimeVax Immuno-Oncology Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.